Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors
Funding to Support the Company’s Commercialization Plans for Twirla ® PRINCETON, N.J. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credit  facility with Perceptive...
Toggle Summary Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco
PRINCETON, N.J. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the company will present at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco . Al Altomari , Chairman and Chief Executive Officer, will...
Toggle Summary Agile Therapeutics Strengthens Commercial Leadership Team
PRINCETON, N.J. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Kimberly Whelan as Vice President of Market Access. Ms. Whelan has over 35 years of experience in the healthcare industry working in finance,...
Toggle Summary Agile Therapeutics to Present at Biotech Showcase™ 2020 in San Francisco
PRINCETON, N.J. , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 14 at the Hilton San Francisco Union Square ....
Toggle Summary Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
PRINCETON, N.J. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration ( FDA ) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application...
Toggle Summary Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)
Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval PRINCETON, N.J. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced a positive outcome from today’s meeting of the Bone, Reproductive and Urologic Drugs Advisory...
Toggle Summary Agile Therapeutics Reports Third Quarter 2019 Financial Results
FDA Advisory Committee Meeting for Twirla® NDA Scheduled for October 30, 2019 Cash Expected to Enable Company to Fund Operations through end of First Quarter 2020 PRINCETON, N.J. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today...
Toggle Summary Agile Therapeutics to Present at Upcoming Investor Conferences
PRINCETON, N.J. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics , Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at two upcoming investor conferences in New York City , where he will provide an...
Toggle Summary Agile Therapeutics Announces Full Exercise of Over-Allotment Option by Underwriters
PRINCETON, N.J. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,894,736...
Toggle Summary Agile Therapeutics Announces Pricing of $12 Million Underwritten Public Offering of Common Stock
PRINCETON, N.J. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 12,631,579 shares of its common stock at a public offering price of $0.95 per share....
Shadow